Galapagos has launched a Phase 2 trial testing the safety and effectiveness of their investigational new therapy called GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF), reporting that the first participant has now received the therapy. GLPG1205 is an anti-inflammatory small molecule that specifically inhibits GPR84, a protein that promotes…
Treatment with Ofev (nintedanib) offers less clinical benefit to patients with severe idiopathic pulmonary fibrosis (IPF) than to those with mild-to-moderate disease, but does improve outcomes if these patients are able to continue on treatment over the longer term, a new study shows. Controlling the therapy’s side effects will be essential…
The incidence of lung cancer is greater among patients with idiopathic pulmonary fibrosis (IPF), compared with the general population, and is associated with a worse prognosis, a new U.S. study reports. The study, “Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease –…
Galecto Biotech is planning a new international Phase 2/3 clinical trial to evaluate inhaled TD139, its investigational candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF). The design of the study, which will be conducted at several clinical centers across Europe and North America, has already been…
With the U.S. midterm elections now less than two weeks away, patient advocacy groups are solidly focused on a range of hot-button issues, from the Orphan Drug Tax Creditand affordable health insurance to future funding for rare disease research. Yet “whether Democrats take over the House or Senate, or…
East River BioSolutions has received a $224,566 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) to advance the development of laboratory tools that can aid in the study of idiopathic pulmonary fibrosis (IPF). Development of effective therapies for IPF…
A mutation associated with the mucous-producing gene MUC5B, a known genetic risk factor for idiopathic pulmonary fibrosis (IPF), also is prevalent in rheumatoid arthritis patients with interstitial lung disease (ILD), according to a study led by researchers from the University of Colorado School of Medicine. The study, “MUC5B Promoter…
Mesenchymal stem cells derived from the bone marrow of people with idiopathic pulmonary fibrosis (IPF) perform basic cell functions, like growing and dividing, more poorly than do these cells from healthy people of the same age, a study reports. The study, “Senescence of bone marrow-derived mesenchymal stem cells from…
The Pulmonary Fibrosis Foundation (PFF) is now accepting applications for a new program, called PFF Scholars, that aims to support and further develop promising researchers working in the field of pulmonary fibrosis (PF). The PFF Scholars program was designed to provide emerging researchers with financial resources to conduct or…
The Pulmonary Fibrosis Foundation (PFF) created an educational website to increase awareness about this disease, with a goal of promoting earlier diagnosis among pulmonary fibrosis (PF) patients. The website includes a video explaining the disease and outlining possible causes, stories from people with the disease, and offers a downloadable Pulmonary Fibrosis…
Get regular updates to your inbox.
